Sobi opens European and Benelux office in Brussels
(Thomson Reuters ONE) -
Today Sobi (Swedish Orphan Biovitrum AB (publ)) formally opened its new European
and Benelux office in Brussels, Belgium. The inauguration, celebrated today with
a ribbon-cutting ceremony, results from Sobi's expanding international presence
and further strengthens the company's platform in Europe as well as in the
Benelux Region.
"Brussels provides an ideal location for our European operations", said Hege
Hellstrom, President EMENAR at Sobi. "Being a company dedicated to rare
diseases, Brussels is of vital importance to Sobi from a business, regulatory,
policy and stakeholder interaction perspective. The Belgian authorities have
also consistently been thought leaders in collaborative, cross-border approaches
to access and availability of rare disease therapies for patients."
The Brussels office will act as an operational hub for Sobi's business and is
consistent with the strategic importance of Europe for Sobi, representing
approximately 60 per cent of the company's global annual product sales. The
office will also enable additional focus on the business in the Benelux region.
The opening of the new office in Brussels is a next step in Sobi's mission to
develop and deliver innovative therapies and services to improve the lives of
patients living with rare diseases. With more than 600 employees and offices in
24 different countries, Sobi currently delivers therapies to patients in 67
countries across the globe. The product portfolio is primarily focused on
Haemophilia, Inflammation and Genetic diseases, and two of the company's
Haemophilia treatments in development are currently being reviewed by the
European Medicines Agency.
- - -
About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Haemophilia, Inflammation and Genetic diseases. We also market a
portfolio of specialty and rare disease products for partner companies across
Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion
(?265 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com.
For more information please contact:
Corporate media relations
Oskar Bosson, Head of Communications
T:+46 704 107 180
oskar.bosson(at)sobi.com
Regional Contact
Hege Hellstrom, President EMENAR
T: +32 473 888 488
hege.hellstrom(at)sobi.com
Country Contact
Karel Fol, Country Manager Benelux
T: +32 475 555 775
Karel.fol(at)sobi.com
032e_new Brussels office:
http://hugin.info/134557/R/1950301/709036.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via GlobeNewswire
[HUG#1950301]
Unternehmensinformation / Kurzprofil:
Datum: 08.09.2015 - 08:00 Uhr
Sprache: Deutsch
News-ID 418384
Anzahl Zeichen: 3782
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 160 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sobi opens European and Benelux office in Brussels"
steht unter der journalistisch-redaktionellen Verantwortung von
Swedish Orphan Biovitrum AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
